News and Updates

Breakthrough T1D’s first-ever Clinical & Research Congress (CRC 2026), focused entirely on type 1 diabetes (T1D), has come to a close! Check out all our coverage below from the exciting weekend in Philadelphia, PA, where researchers, clinicians, industry leaders, healthcare professionals (HCPs), and the T1D community united to share updates across our entire mission. Updates […]

It’s a rainy day in Philadelphia, but the mood at CRC 2026 could not be sunnier! The attendees were positively buzzing (seriously) with how timely and impactful this meeting is. It’s the right time for a meeting focused exclusively on type 1 diabetes (T1D), and the good news is we won’t have to wait years […]

We are two days into the first ever Breakthrough T1D Clinical & Research Congress! Day 1 was full of optimism and excitement about the meeting—it’s really ALL type 1 diabetes (T1D), which is unique—and the future of treatments and therapies for this community. Breakthrough T1D’s Clinical & Research Congress The inaugural Breakthrough T1D Clinical & […]

Hello from Philadelphia, PA! We could not be more thrilled that, after years and years, we have finally kicked off our inaugural Breakthrough T1D Clinical & Research Congress (CRC). This groundbreaking event is focused entirely on type 1 diabetes (T1D), and it’s happening right now! Breakthrough T1D’s Clinical & Research Congress The inaugural Breakthrough T1D […]

Heart and kidney complications remain a major concern for people living with type 1 diabetes (T1D). While there are some therapies available to reduce the risk of these complications, the T1D community urgently needs more options. SGLT inhibitors (SGLTi), which have proven effective in people with type 2 diabetes (T2D) and people without diabetes, are […]

After months and months of preparation, it’s finally here! Breakthrough T1D’s very first Clinical & Research Congress (CRC), a groundbreaking event focused entirely on type 1 diabetes (T1D), is happening this week from October 9-11 in Philadelphia, PA. Bringing Together People United in Our Shared Goal This scientific meeting is a groundbreaking event, uniting T1D […]

Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to […]

Finerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a measure of kidney damage, and reducing […]

New Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about […]

To accomplish our mission of a world without type 1 diabetes (T1D), one thing is clear: the more minds we have thinking about T1D, the better. That’s why Breakthrough T1D brings in interns each year, including in our Research department. Training the next generation isn’t just about career development—it’s about fresh eyes, new ideas, diverse […]